FŞFikri Selçuk Şimşek

Fikri Selçuk Şimşek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fikri Selçuk Şimşek has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    18F-FDG PET/CT–Detected Imaging Findings in Graft Intolerance Syndrome: Two Case Reports

    by Merve Yücel Kahraman, Fikri Selçuk Şimşek, Tarık Şengöz, Aziz Gültekin, İlknur Girişgen, Tülay Becerir

    Graft intolerance syndrome (GIS) is a relatively common but often overlooked clinical condition that may develop following renal graft failure. It usually occurs within the first year after resumption of dialysis. It is characterized by persistent inflammatory findings in the absence of infection and may adversely affect patient prognosis if not recognized in a timely manner. In this study, 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings of two renal transplant recipients with clinical suspicion of GIS are presented. In both cases, diffuse increased FDG uptake was observed in the graft parenchyma on PET/CT imaging. In one case, hypermetabolic lymph nodes observed in the para-aortic region were additionally evaluated as reactive. The diagnosis of GIS was established based on imaging findings together with clinical and laboratory data. FDG PET/CT can demonstrate characteristic inflammatory uptake patterns. It may also help exclude alternative etiologies such as infection or malignancy in the evaluation of GIS.

  • Nephrotoxicity and hematotoxicity associated with Lu-177 PSMA radioligand therapy in prostate cancer

    by Tarık Şengöz, Onur Cumhur Çimen, Ali Çelik, Aziz Gültekin, Fikri Selçuk Şimşek

    Aims: Lutetium-177 (Lu-177) PSMA radioligand therapy (PRLT) is an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Treatment-related nephrotoxicity and hematotoxicity can occur. In our study, we investigated the development of nephrotoxicity and hematotoxicity after Lu-177 PRLT applied to mCRPC patients in our department.Methods: All patients diagnosed with mCRPC who applied to our department between March 2018 and May 2025 and received at least 3 courses of Lu-177 PRLT were included in the study. The study was designed retrospectively. Patient information was obtained from patient treatment files and the hospital system. Patients were divided into two groups: those who received 3 courses of Lu-177 PRLT (group 1) and those who received ≥4 courses of Lu-177 PRLT (group 2). For the evaluation of hematotoxicity and nephrotoxicity, blood values were used in group 1 patients before treatment (on the day of the first cycle) and at the end of treatment (1 month after the third and final cycle); and in group 2 patients before treatment (on the day of the first cycle), interim (1 month after the third cycle), and at the end of treatment (1 month after the final cycle). Hematological and renal toxicity were determined according to the “Common Terminology Criteria for Adverse Events (CTCAE v5.0)”. Results: The study included 43 male patients (16 (37.3%) in group 1, 27 (62.7%) in group 2). The mean age was 69.74±7.86 years. In group 1 patients, post-treatment glomerular filtration rate (eGFR), red blood cells (RBC), hemoglobin (Hb), hematocrit (Htc), platelets (PLT), white blood cell count (WBC), and lymphocyte values were statistically significantly lower than pre treatment values, while creatinine values were higher. In Group 2 patients, post-treatment and interim eGFR, RBC, Hb, Htc, mean corpuscular hemoglobin volume (MCV), mean corpuscular hemoglobin (MCH), PLT, WBC, and lymphocyte values were statistically significantly lower than pre-treatment values, while creatinine levels were higher. When toxicity was assessed according to CTCAE v5.0, nephrotoxicity was detected in 2 patients (grade 2 and 3) (4.7%) and hematotoxicity in 3 patients (grade 2, 3 and 4) (7%) after treatment. No significant differences were found between the groups that received/did not receive chemotherapy before Lu-177 PRLT, and between pre- and post-treatment blood parameters.Conclusion: Although post-treatment deterioration in blood parameters indicating hematological and nephrological side effects was observed in patients diagnosed with mCRPC following Lu-177 PRLT, toxicity assessment according to CTCAE v5.0 revealed low levels of hematotoxicity and nephrotoxicity. Lu-177 PRLT is a safe treatment that can be applied with appropriate patient selection and monitoring.

  • Health‐Related Quality of Life in Differentiated Thyroid Cancer Survivors: A Cross‐Sectional Study From Turkey

    by Aziz Gültekin, Merve Yücel Kahraman, Tarık Şengöz, Fikri Selçuk Şimşek

    Background: To evaluate the health‐related quality of life (HRQoL) in patients with differentiated thyroid cancer (DTC) and to identify clinical and demographic factors associated with HRQoL outcomes. Methods: This cross‐sectional study included 202 patients diagnosed with differentiated thyroid cancer who completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30 (EORTC QLQ‐C30) questionnaire. Sociodemographic and clinical data such as age, sex, educational status, employment, tumor size, ATA risk classification, TNM stage, and radioactive iodine (RAI) therapy were recorded. Statistical analyses included descriptive statistics, non‐parametric tests, Spearman correlation, and multivariable linear regression to determine predictors of global HRQoL score. Results: The median global HRQoL was 58.3 (IQR: 50.0–75.0). Functional scores were highest in role, emotional, cognitive, and social domains (median 66.7). Fatigue was the most prominent symptom (median: 44.4), followed by pain, dyspnea, and insomnia (each 33.3). Female sex, lower educational level, and higher RAI dose were associated with lower global HRQoL scores. Emotional functioning was significantly lower in patients aged ≥ 55 years. Multivariable regression analysis identified sex, education level, RAI dose, and TNM stage as significant predictors of HRQoL. Conclusion: Despite generally favorable prognoses in DTC, multiple demographic and treatment‐related variables significantly influence patient‐reported HRQoL. RAI therapy and disease stage may impact HRQoL less than previously assumed. These findings highlight the importance of individualized supportive care strategies in survivorship plans.


  • A retrospective evaluation of the pulmonary function tests and quality of life assessment surveys of emphysema patients subject to coil treatment

    by Erhan Uğurlu, Nazlı Çetin, Nilüfer Yiğit, Ümit Aydoğmuş, İlKnur Hatice Akbudak, Hande Şenol, Fikri Selçuk Şimşek, Göksel Altınışık

    Bronchoscopic volume reduction treatments are among the important alternatives for selected emphysema patients with a dyspneic course despite optimal medical treatment. Our aim was to carry out a retrospective scan of the data for COPD patients subject to coil treatment at our center for assessing whether coil procedure has an impact on the respiratory symptom and pulmonary function tests in COPD patients. The data of 41 patients with severe emphysema and treated with coils between 2017-2020 were evaluated retrospectively. Cardiopulmonary rehabilitation programs were completed for all patients prior to the procedure and they were assessed with pulmonary function test (PFT), diffusing capacity for carbonmonoxide test (DLCO), body plethysmography, 6-minute walk test, ventilation/perfusion scintigraphy, St. George's Respiratory Questionnaire (SGRQ). Data acquired prior to the procedure and 3rd month control data after the procedure were recorded and SGRQ was applied via face-to-face interviews during the controls by doctors working on Pulmonary Diseases as was the case before the procedure. SGRQ questionnaires of 32 patients were evaluated. Statistically significant changes were observed after the procedure in symptom, activity, impact score and total score which were calculated prior to the procedure. Pre and post procedure FEV1, FVC, FEV1/FVC, PEF, FEF25/75 parameters were used for the comparison made via SFT. Statistically significant changes were observed in FEV1, FVC, FEF25/75 when the pre and post-procedure SFT parameters of the 32 patients included in the study were compared. A statistically significant improvement was observed in the PFT parameters and quality of life questionnaires following the coil procedure which is a bronchoscopic volume reduction procedure.


  • An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions

    by Fikri Selcuk Simsek, Muhammet Arslan, Yusuf Dag

    In some non-small cell lung cancer (NSCLC) patients, lipid-poor adrenal adenomas cannot be adequately differentiated from metastases using imaging methods. Invasive diagnostic procedures also have a low negative predictive value (NPV) in such cases. The current study aims to establish a specific and clinically practical metabolic parameter for lipid-poor adrenal lesions (ALs) in NSCLC patients. This diagnostic approach may prevent unnecessary abdominal enhanced computed tomography (CT), magnetic resonance imaging, or invasive diagnostic procedures. Sixty-four NSCLC patients with 69 lipid-poor ALs and 28 control patients with 30 benign lipid-poor ALs, who underwent FDG-PET/CT, were retrospectively reviewed. Two morphological and four metabolic parameters were analyzed in FDG-PET/CT images of NSCLC and control patients. Baseline and post-chemotherapy images of 64 NSCLC patients were re-evaluated according to the PERCIST 1.0. In cases where ALs could not be differentiated, follow-up FDG-PET/CT images were re-examined. The receiver operating characteristic (ROC) curve method was used for the evaluation of diagnostic parameters. Out of 69 ALs, 39 were determined as metastatic lesions (adrenal metastasis), while 30 lesions were considered non-metastatic (adrenal adenomas). The mean attenuation value, SUVmax AL/SUVmax primary tumor, SUVmax, SUVmax AL/liver, and SUVmax AL/SUVmean liver were significantly different between metastatic and benign ALs from NSCLC patients. The SUVmax AL/SUVmean liver ≥1.81 had the best positive (PPV, 94.3%) and negative (NPV, 82.4%) predictive values, and the highest specificity (93.3%), sensitivity (84.6%) and accuracy (86.9%). Lipid-poor ALs with SUVmax AL/SUVmean liver ≥1.81 can be accepted as malignant in NSCLC. However, if SUVmax AL/SUVmean liver is <1.81, a pathologic examination is required. Utilizing this cut-off value to decide on adrenal core biopsy may prevent its unnecessary use. Moreover, this diagnostic approach can save time and reduce the healthcare costs.


  • Open Access

    The Role of Pre-ablative Stimulated Thyroglobulin and Thyroglobulin/ Thyroid-Stimulating Hormone Ratio for Predicting Metastasis in Thyroid Cancer

    by Fadime Demir, Fikri Selçuk Şimşek, Tansel Ansal Balcı

    In this study, we aimed to investigate the predictive value of pre-ablative stimulated thyroglobulin (Tg) and Tg/thyroid-stimulating hormone (TSH) to identify lymph node metastasis (LNM) or distant metastases (DM) prior to radioactive iodine (RAI) treatment. Patients without metastasis were included in group 1 (n=100), those with LNM were included in group 2 (n=83), and those with DM constituted group 3 (n=23). Tg and TSH values were measured approximately 4 hours prior to RAI ablation therapy. There was a significant difference between group 3 and other groups (group 1 and group 2) in terms of Tg (p<0.001) and Tg/ TSH (p<0.001). For Tg level and Tg/TSH ratio, the areas under ROC were 0.990 [95% confidence interval (CI): 0.979-1] and 0.991 (95% CI: 0.981-1), respectively. The cut-off points for Tg and Tg/TSH were 102 ng/mL and 1.06, respectively. Our results suggest that Tg and Tg/TSH values can be used to predict DM. On the other hand, our study indicates that patients should be carefully evaluated for LNM even when Tg levels are l ow.


  • 693 Hounsfield unit has the ability to predict positive stone culture prior to percutaneous nephrolitotomy

    by Y. Tanidir, A. Garayev, A. Sahan, T.E. Sener, I. Tinay, C.A. Sekerci, C. Akbal, F. Simsek